Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 2Prostatic Neoplasms 1Multiple Myeloma 1Lung Neoplasms 1Leukemia, Plasma Cell 1Ganglioneuroblastoma 1Adenoma, Islet Cell 1

Interventions

enzalutamide 21Magnetic Resonance Spectroscopy 21apalutamide 17Androgen Antagonists 14Specimen Handling 13Prednisone 13Abiraterone Acetate 13abiraterone 9Docetaxel 9Radiotherapy 8Biopsy 8darolutamide 7Radiosurgery 7Pluvicto 7Nivolumab 7cabazitaxel 6Lutetium-177 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6Lutetium 5radium Ra 223 dichloride 4pembrolizumab 4niraparib 4gallium 68 PSMA-11 4cabozantinib 4bicalutamide 4atezolizumab 4Watchful Waiting 4Surveys and Questionnaires 4Standard of Care 4Radiotherapy, Intensity-Modulated 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × sargramostim × 30 days × Clear all
NCT03600350 2026-06-01

pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer

University of Wisconsin, Madison

Phase 2 Active not recruiting
19 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡